Cost of Revenue Trends: Amgen Inc. vs Supernus Pharmaceuticals, Inc.

Cost of Revenue Trends: Amgen Inc. vs Supernus Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Over the past decade, Amgen Inc. and Supernus Pharmaceuticals, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Amgen's cost of revenue surged by approximately 90%, reflecting its expansive growth and increased production capabilities. In contrast, Supernus Pharmaceuticals, Inc. experienced a more modest increase of around 1,350%, albeit from a much smaller base, highlighting its rapid scaling efforts.

Key Insights

• Amgen Inc.: Starting at 4.4 billion in 2014, Amgen's cost of revenue peaked at 8.4 billion in 2023, indicating robust growth and market expansion.
• Supernus Pharmaceuticals, Inc.: Despite starting with a modest 5.8 million in 2014, Supernus reached 87.2 million by 2023, showcasing its aggressive growth strategy.

These trends underscore the diverse strategies and market positions of these pharmaceutical giants.